Harvard Medical School and Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Medical School, University of Massachusetts, Worcester, MA, USA.
Expert Opin Biol Ther. 2020 Jun;20(6):621-633. doi: 10.1080/14712598.2020.1732918. Epub 2020 Mar 6.
: Hidradenitis suppurativa (HS) is a chronic skin disorder characterized by inflammatory nodules, abscesses, and fistulae. Patients tend to present in young adulthood and are predominantly female. The pathogenesis of HS involves apopilosebaceous gland follicle occlusion and affected areas often occur where this type of gland predominates. Treatment selection depends on HS severity, which is included in different scoring systems. In recent years, biological therapies have been evaluated and used with increasing frequency in moderate-to-severe HS disease.: This review focuses on biological therapies for HS as assessed in case reports, case series, and clinical trials. The efficacy, hidradenitis suppurativa scoring systems, and long-term results of these therapies are discussed depending on the studies' endpoints.: Adalimumab is currently the only FDA-approved HS biological therapy. Some patients do not experience treatment efficacy with adalimumab at 40 mg/week, which may result in increasing the dose or seeking other treatments. Infliximab is the next line of HS treatment with demonstrated efficacy. Other biological therapies being studied have demonstrated efficacy in small patient groups, but lack study power. Further studies may provide answers to seeking treatment options for patients who fail to improve on current standard HS treatment.
: 化脓性汗腺炎（HS）是一种慢性皮肤疾病，其特征为炎症性结节、脓肿和瘘管。患者通常在成年早期出现，以女性为主。HS 的发病机制涉及顶泌汗腺的毛囊阻塞，受影响的区域通常发生在这种腺体占主导地位的地方。治疗选择取决于 HS 的严重程度，这包含在不同的评分系统中。近年来，生物疗法已被评估，并在中重度 HS 疾病中越来越频繁地使用。: 本综述重点关注在病例报告、病例系列和临床试验中评估的 HS 的生物疗法。根据研究终点，讨论了这些疗法的疗效、化脓性汗腺炎评分系统和长期结果。: 阿达木单抗是目前唯一获得 FDA 批准的 HS 生物疗法。一些患者在每周 40 毫克的阿达木单抗治疗下没有疗效，这可能导致增加剂量或寻求其他治疗方法。英夫利昔单抗是 HS 的下一线治疗方法，已被证明具有疗效。其他正在研究的生物疗法在小患者群体中显示出疗效，但缺乏研究动力。进一步的研究可能会为那些对当前标准 HS 治疗没有改善的患者提供治疗选择。
